ReviewAntiviral research2025
Epigenetic drugs against human DNA viruses and retroviruses.
Review in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Epigenetic drugs offer an attractive strategy against DNA viruses and retroviruses that establish chronic infections mimicking the chromatinized host genome. Direct-acting antiviral (DAA) drugs that inhibit viral replication decrease viremia. However, they fail to eradicate the nuclear reservoirs of viral DNA that masquerade as host chromatin, which enable viral genome maintenance and reactivation with possible severe clinical sequelae. Owing to the strides in basic epigenetic and translational research endeavors, we enter a new era of drug development against infections with persistent or latent DNA virus and retroviruses including drugs that target the host epigenetic mechanisms hijacked by the viruses. Epigenetic drugs modulate the virus-host arms race, fortifying host defenses by remodeling the epigenetic landscape inside cells, silencing persistent viral genomes, or inducing massive simultaneous reactivation of latent reservoirs in the presence of DAA. This review aims to highlight the successes, progress, and challenges of this approach by analyzing the emerging preclinical and clinical studies of epigenetic drugs against the retroviruses human immunodeficiency virus (HIV) and human T-cell lymphotropic virus-1 (HTLV-1), the pararetrovirus hepatitis B virus (HBV), and the herpesviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.